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Recent studies have demonstrated that submicromolar
concentrations of the biocide triclosan arrest the growth of
the apicomplexan parasites Plasmodium falciparum and
Toxoplasma gondii and inhibit the activity of the apicom-
plexan enoyl acyl carrier protein reductase (ENR). The crystal
structures of T. gondii and P. falciparum ENR in complex with
NAD+ and triclosan and of T. gondii ENR in an apo form have
been solved to 2.6, 2.2 and 2.8 A˚, respectively. The structures
of T. gondii ENR have revealed that, as in its bacterial and
plant homologues, a loop region which flanks the active site
becomes ordered upon inhibitor binding, resulting in the slow
tight binding of triclosan. In addition, the T. gondii ENR–
triclosan complex reveals the folding of a hydrophilic insert
common to the apicomplexan family that flanks the substrate-
binding domain and is disordered in all other reported
apicomplexan ENR structures. Structural comparison of the
apicomplexan ENR structures with their bacterial and plant
counterparts has revealed that although the active sites of the
parasite enzymes are broadly similar to those of their bacterial
counterparts, there are a number of important differences
within the drug-binding pocket that reduce the packing
interactions formed with several inhibitors in the apicom-
plexan ENR enzymes. Together with other significant
structural differences, this provides a possible explanation of
the lower affinity of the parasite ENR enzyme family for
aminopyridine-based inhibitors, suggesting that an effective
antiparasitic agent may well be distinct from equivalent
antimicrobials.
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1. Introduction
The widespread use of antimalarial agents such as quinolines,
antifolates and atovaquone/proguanil has provided a powerful
selective pressure driving the development of multidrug
resistance in several malarial strains. This increase in resis-
tance of Plasmodium falciparum, the most dangerous and
widespread species of malarial parasite, and the lack of
development of novel low-cost antimalarial medicines has
contributed to the rise in the incidence of malaria, which
currently kills more than two million people annually
(Breman, 2001). Furthermore, the closely related apicom-
plexan parasite Toxoplasma gondii is estimated to infect 25%
of the world’s population (Sibley, 2003). Moreover, it has been
reported as being responsible for the deaths of a significant
number of European patients suffering from acquired immu-
nodeficiency syndrome (Hill & Dubey, 2002) and is the third
most common cause of food-borne deaths in the United States
(Mead et al., 1999). T. gondii parasites can also be passed from
mother to foetus during pregnancy, leading to congenital
ophthalmological neurological defects (Boyer & McLeod,
2002). The total healthcare burden of toxoplasmosis is esti-
mated to be up to $5 billion per annum within the USA and
there are still no currently available treatments that eliminate
the latent form of the parasite.
Recent studies have revealed that it may be possible to
control apicomplexan parasite infections by targeting
processes that reside in their apicoplast organelle, which
contains over 500 different proteins responsible for carrying
out a number of key metabolic pathways (Waller et al., 1998;
Zuther et al., 1999). This organelle is thought to have arisen
through the process of secondary endosymbiosis. Thus, the
apicomplexan progenitor endocytosed an ancient alga which
contained a cyanobacterial-derived plastid obtained in a
previous primary endosymbiotic event. Consistent with this,
analysis of the genes encoding the enzymes of apicoplast-
located pathways suggests that they are closely related to
those found in prokaryotes and the chloroplasts of plants
(Zuther et al., 1999; Fast et al., 2001; Kohler et al., 1997). For
example, in apicomplexan parasites the fatty-acid biosynthesis
pathway resembles the type II fatty-acid synthase that is found
in bacteria and plant chloroplasts and in which each catalytic
step of the pathway is encoded on a separate polypeptide
(Magnuson et al., 1993), rather than the type I FAS found in
man (Smith, 2003). Enoyl acyl carrier protein reductase
(ENR) carries out one of two reductive steps in the type II
FAS pathway and has been shown to be the target of several
families of antimicrobial compounds, including the diaza-
borines (Baldock et al., 1996), aminopyridine-based inhibitors
(Payne et al., 2002; Seefeld et al., 2003) and triclosan (Levy et
al., 1999; Fig. 1), a biocide which is found in many household
formulations such as toothpastes, soaps, mouthwashes and
plastics (Bhargava & Leonard, 1996).
Sequence alignment of T. gondii and Plasmodium ENRs
reveals considerable similarity to the enzymes from other
species, with the closest resemblance being to those of plant
rather than bacterial origin, with for example approximately
50% sequence identity between Brassica napus and T. gondii
ENR (Fig. 2). Compared with other ENRs, a striking feature
of the Plasmodium ENR enzymes is the presence of a large
polar low-complexity insert of variable size which is thought to
flank the substrate-binding pocket. In T. gondii ENR, a similar
but smaller insert consisting of only six residues can be
observed. In the bacterial enzymes, only the ENR from
Mycobacterium tuberculosis (MtENR) shows a significant
insert at this position. However, in MtENR this insert has
been implicated in allowing the enzyme to accommodate
larger substrates such as mycolic fatty acids (Rozwarski et al.,
1999) and its glycine-rich hydrophobic nature is in contrast to
that found in the apicomplexan ENRs, which contain a
predominantly polar hydrophilic insert of unknown function.
Recently, triclosan has been shown to retard the growth of
T. gondii and P. falciparum with an IC50 of less than 1 mM and
with a Ki of 0.4 nM for the P. falciparum ENR enzyme
(Kapoor et al., 2001; McLeod et al., 2001; Surolia & Surolia,
2001). However, a major challenge for the development of
drugs targeted against the apicomplexan family is the need for
the inhibitor to cross the four membranes of the apicoplast in
addition to the barriers provided by the host cell and parasite.
Further problems in drug delivery arise when targeting the
bradyzoite stage of T. gondii, in which the parasites reside
within a cyst composed of host and parasite constituents.
Recent studies have shown that triclosan has been observed to
retard the growth of both P. falciparum and T. gondii
trachyzoites (McLeod et al., 2001; Surolia & Surolia, 2001);
moreover, the attachment of triclosan to a releasable octa-
arginine linker produced a potent antiparasitic agent that
could also enter encysted T. gondii bradyzoites (Samuel et al.,
2003).
In this paper, we report the structures of apo T. gondii ENR
(TgENR) and of both TgENR and P. falciparum ENR
(PfENR) in complex with NAD+ and triclosan solved to 2.9,
2.6 and 2.2 A˚, respectively. The structures have allowed
comparisons to be made with those of ENRs from bacterial
and plant origin in order to identify novel features of the
enzyme that could be utilized in a program of rational drug
design.
2. Materials and methods
2.1. Structure determination of PfENR
PfENR is a tetramer with a molecular weight of approxi-
mately 38 000 Da and its overexpression, purification and
crystallization were carried out as reported previously
(Muench et al., 2003). Data were collected to 2.2 A˚ using an
ADSC Quantum 4 detector at station 14.1 at the Daresbury
Synchrotron Radiation Source (SRS) at 100 K using 20%(v/v)
glycerol as a cryoprotectant. Analysis of the diffraction data
using the autoindexing routine in the program DENZO
(Otwinowski & Minor, 1997) showed that the crystals belong
to the primitive monoclinic system, with
unit-cell parameters a = 88.2, b = 82.4,
c = 94.8 A˚,  =  = 90,  = 90.8 and a
tetramer in the asymmetric unit. The
data were subsequently processed using
the DENZO/SCALEPACK (Otwi-
nowski & Minor, 1997) package and
analysis of the pattern of systematic
absences was consistent with the space
group being assigned as P21. Data-
collection and processing statistics are
given in Table 1.
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Figure 1
The structural formulae of (a) triclosan and (b) (E)-N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)-
3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-ylacrylamide (compound 29) produced using the
program ISIS/Draw.
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Figure 2
A structure-based sequence alignment of the ENR enzymes from P. falciparum, P. knowlesi, P. vivax, P. chabaudi, P. yoelii, B. napus, E. coli,
M. tuberculosis and T. gondii. The elements of secondary structure and the sequence numbering, which is from the start of the mature enzyme for the
P. falciparum and T. gondii enzymes, are shown above and below the alignment, respectively, with cylinders representing -helices and arrows -strands.
Residues fully conserved in the above sequences are shown in black boxes and residues which are within 4 A˚ of the inhibitor triclosan are highlighted by
a black circle. Those residues which form the conserved SGE motif (residues 238–240 in TgENR) are enclosed by a black box.
Phases for the ternary PfENR–NAD+–triclosan complex
were determined by the molecular-replacement method using
the program AMoRe (Navaza, 1994) and the structure of the
B. napus ENR–NAD+ complex (PDB code 1eno) as a search
model, from which the coordinates for the NAD+ and triclosan
were omitted. Following a clear solution of the rotation/
translation function, the model was subjected to rigid-body
refinement using REFMAC5 (Murshudov et al., 1997) using
data in the resolution range 10–3.0 A˚. The resulting electron-
density maps were examined and revealed clear density in
each of the four subunits of the tetramer for both NAD+ and
triclosan. The model was subsequently subjected to TLS
refinement in REFMAC5 (Murshudov et al., 1997) and rebuilt
in an iterative process using data to 2.2 A˚. Following model
building, solvent molecules were added using the program
ARP (Lamzin & Wilson, 1997), but were only refined if they
made appropriate contacts to the protein and had B factors
below 60 A˚2. Analysis using the program PROCHECK
(Laskowski et al., 1993) shows that
no nonglycine residues lie within
disallowed regions of the Rama-
chandran plot, with 90.7 and 9.3%
being in the most favoured and
additionally allowed regions,
respectively. The final refinement
statistics are given in Table 1.
2.2. Structure determination of the
TgENR–NAD+–triclosan complex
The overexpression, purification
and crystallization of the TgENR–
NAD+–triclosan complex were
carried out as described previously
(Muench et al., 2006). Preliminary
X-ray analysis of crystals flash-
frozen in 25% glycerol showed
that they diffracted well to 2.6 A˚
resolution. A complete data set was
subsequently collected to 2.6 A˚
resolution at 100 K using a rotation
oscillation of 1 over 90 and an
exposure time of 10 min on a
MAR345 image-plate detector
mounted on a Rigaku MM007
generator. Analysis of the diffraction
data using the autoindexing routine
in the program DENZO (Otwi-
nowski & Minor, 1997) showed that
the crystals belong to the trigonal
point group 32, with unit-cell para-
meters a = 78.1, b= 78.1, c= 188. 5 A˚,
 =  = 90,  = 120. Analysis of
systematic absences suggested that
the space group was either P3221 or
P3121. Assuming that the asym-
metric unit contains a dimer, the VM
value is 2.4 A˚3 Da1 for the TgENR–NAD+–triclosan crystals,
which is within the range of VM values observed for protein
crystals (Matthews, 1977). The data were subsequently
processed using the DENZO/SCALEPACK (Otwinowski &
Minor, 1997) package. Data-collection and processing statis-
tics are given in Table 1.
The structure of the TgENR–NAD+–triclosan complex was
determined by molecular replacement using the program
AMoRe (Navaza, 1994) with the PfENR–NAD+–triclosan
complex structure as a search model, from which the coordi-
nates for the NAD+ and triclosan were omitted along with
those residues believed to adopt different positions in TgENR
and PfENR (63–75, 93–108 and 238–241). The resulting
rotation/translation solution gave a clear solution in space
group P3221. The model was subjected to rigid-body refine-
ment using REFMAC5 (Murshudov et al., 1997) and data in
the range 20–4.0 A˚. The model was subsequently rebuilt and
refined in an iterative process using TLS refinement in
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Table 1
Data-collection and refinement statistics for apo TgENR, PfENR–NAD+–triclosan and TgENR–
NAD+–triclosan complexes.
Values in parentheses are for the highest resolution shell. N/A, not applicable.
PfENR–NAD+–
triclosan
TgENR–NAD+–
triclosan Apo TgENR
Data-collection statistics
Space group P21 P3221 P3221
Wavelength used (A˚) 0.9600 1.542 1.542
Resolution range (A˚) 50–2.2 (2.26–2.2) 30–2.6 (2.7–2.6) 30.0–2.9 (3.0–2.9)
Unique reflections 77321 21105 13758
Multiplicity 3.1 5.2 10.1
Completeness (%) 97.2 (94.7) 99.9 (99.4) 99.7 (99.8)
I/(I) > 3 (%) 72.6 (49.6) 74.4 (42.0) —
Average I/(I) — — 16.2 (4.5)
Rmerge† (%) 0.095 (0.395) 0.082 (0.48) 0.18 (0.65)
Refinement statistics
Resolution limits (A˚) 30.0–2.2 20.0–2.6 30.0–2.9
Rcryst‡ (%) 20.0 22.0 21.0
Rfree§ (%) 25.5 28.0 28.0
R.m.s.d. values
Bond lengths (A˚) 0.02 0.015 0.012
Bond angles () 1.8 1.7 1.4
Ramachandran plot}
Most favoured (%) 90.7 89.0 89.0
Additionally allowed (%) 9.3 11.0 11.0
Generously allowed (%) 0.0 0.0 0.0
Disallowed (%) 0.0 0.0 0.0
Molecules in ASU 4 2 2
Protein atoms 9161 4514 4288
Substrate atoms 244 122 0
Water molecules 493 37 11
Mean B values (A˚2)
Protein†† 22.0 [21.0] 57.0 [56.0] 42.0 [41.0]
Cofactors 23.0 54.0 N/A
Water molecules 23.0 45.0 26.0
Missing residues Ala1–Glu14 (A, B, C),
Ala1–Lys12 (D),
Lys242–Asn282 (A, B, C),
Asn241–Asn282 (D),
Asn347–Glu340 (A, B),
Glu348–Glu340 (C),
Arg346–Glu340 (D)
Ser1–Phe3 (A),
Ser1–Ala2 (B),
Ser238–Gly239 (B),
Leu307–Asn315
(A, B)
Ser1–Phe3 (A),
Ser1–Ala2 (B),
Leu227–Lys241 (A),
Leu227–Ser242 (B),
Leu307–Asn315
(A, B)
† Rmerge =
P
hkl jIi  Imj=
P
hkl Im, where Ii and Im are the observed intensity and mean intensity of related reflections,
respectively. ‡ Rcryst =
P
hklðjFobsj  jFcalcjÞ=
P
hkl jFobsj. § Rfree was calculated for 5% of the data omitted random-
ly. } Percentage of residues in regions of the Ramachandran plot according to PROCHECK (Laskowski et al.,
1993). †† Values in square brackets are the B factor for main-chain atoms only.
REFMAC5 (Murshudov et al., 1997) using data in the range
20–2.6 A˚ with the addition of water atoms being carried out
using the program ARP (Lamzin & Wilson, 1997) in the same
manner as for the PfENR enzyme. Analysis using the program
PROCHECK (Laskowski et al., 1993) showed that no non-
glycine residues lie in the disallowed regions of the Rama-
chandran plot, with 89% and 11% being in the most favoured
and additionally allowed regions, respectively. The final
refinement statistics are given in Table 1.
2.3. Structure determination of apo TgENR
Crystals of apo TgENR were grown in 0.1 M Tris pH 8.5 and
25%(v/v) t-butanol, taking 4 days to reach approximate
dimensions of 0.15  0.1  0.1 mm. These crystals were
subsequently flash-frozen in 30% glycerol and diffracted well
to 2.9 A˚ resolution at 100 K. A data set was collected using a
rotation range of 1 over 200 and an exposure time of 10 min
per degree on a MAR345 image-plate detector mounted on a
Rigaku MM007 generator. These data were subsequently
processed using the programs MOSFLM (Leslie, 1992) and
SCALA (Evans, 1997) and showed that the crystals belonged
to the trigonal point group 32, with unit-cell parameters
a = 76.04, b = 76.04, c = 187. 47 A˚,  =  = 90,  = 120. The
structure of apo TgENR was determined by molecular
replacement using the program AMoRe (Navaza, 1994) with
the TgENR–NAD+–triclosan complex structure as a search
model, from which the coordinates for the NAD+ and triclosan
were omitted along with residues 63–75, 93–108 and 238–241.
The resulting rotation/translation solution gave a clear solu-
tion in space group P3221. The model was subjected to rigid-
body refinement and was subsequently rebuilt and refined in
an iterative process by TLS refinement in REFMAC5
(Murshudov et al., 1997) using data in the range 20–2.9 A˚. An
additional 11 water molecules were added in the same manner
as for the PfENR enzyme. Analysis using the program
PROCHECK (Laskowski et al., 1993) showed that no
nonglycine residues lie in the disallowed regions of the
Ramachandran plot, with 89% and 11% being in the most
favoured and additionally allowed regions, respectively. The
final refinement statistics are given in
Table 1.
The electrostatic surface potentials shown
in Figs. 3(b) and 5 were calculated using the
program GRASP (Nicholls et al., 1991) and
all figures except Fig. 1 and Fig. 4 were
produced in PyMOL (DeLano, 2002). Fig. 4
was produced using the graphics program
TURBO-FRODO (Roussel et al., 1990).
2.4. Sequence identification and alignment
The ENR sequences for the Plasmodium
species P. yoelli, P. vivax, P. knowlesi and
P. falciparum and for T. gondii were taken
from the SWISS-PROT database (accession
Nos. Q7RHY7, Q6TEI3, Q6TEI4, Q9BH77
and Q6UCJ9, respectively). The sequence
for P. chabaudi ENR was obtained
by BLAST searching the PlasmoDB data-
base (http://www.plasmoDB.org) using the
PfENR amino-acid sequence. The
sequences were initially aligned using Clus-
talW (Higgins & Thompson, 1994), edited by
hand and further manipulated within
ALSCRIPT (Barton, 1993) to obtain a
structural alignment diagram (Fig. 2).
3. Results and discussion
3.1. Overall fold of the complexes of
TgENR and PfENR with NAD+ and triclosan
The sequences of PfENR and TgENR
share 42% identity and the folds of the
enzymes are structurally very similar, with
superposition of the core residues giving an
r.m.s.d. of the C atoms of 0.6 A˚. Each
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Figure 3
(a) Stereoview of the TgENR monomer in complex with NAD+ and triclosan, coloured from
blue (N-terminus) to red (C-terminus), with each secondary-structure element labelled. The
atom colours for triclosan and the NAD+ cofactor are yellow, blue, red, purple and green for
carbon, nitrogen, oxygen, phosphorus and chlorine, respectively. (b) Surface representation of
the TgENR monomer, showing the distribution of electrostatic charge. The position of the
inserted loop, which is a feature of the apicomplexan family, is displayed below the partially
transparent depiction of the protein surface as a stick representation and Lys237, which is fully
conserved within the loop region of the apicomplexan family, is labelled. The position of the
NAD+ cofactor and the triclosan inhibitor which define the active site and the ACP-binding
region are shown, demonstrating their proximity to Lys237.
monomer has overall dimensions of 45  50  60 A˚ and
analysis of the secondary structure (as defined by the program
PROMOTIF; Hutchinson & Thornton,
1996) shows that TgENR is formed of nine
-helices (1–9) comprising 108 residues
(36%), seven -strands (1–7) formed by
43 residues (14%), six 310-helices formed
by 18 residues (6%) and a number of
loops. The secondary-structure elements
form an arrangement reminiscent of the
Rossmann fold common to several nucleo-
tide-binding enzymes (Rossmann et al.,
1974), with a parallel -sheet flanked on one
side by helices 3, 4, 5 and 6 and on the
other by helices 1, 2 and 9, with the 7
and 8 helices lying at the C-terminal end of
the -sheet (Fig. 3a). The NAD+ cofactor
binds at the C-terminal end of the -sheet
and makes important interactions with
residues at the end of or following each of
the -strands except for 7. Residues from
helices 5, 6 and 8 form the inhibitor-
binding pocket, with 7 forming a lid over
the inhibitor and making extensive van der
Waals interactions.
To date, several structures of PfENR have
been published in complex with a variety of
inhibitors [PDB codes 1nhg, 1nnu, 1nhw
(Perozzo et al., 2002), 1zsn, 1zw1, 1zxb, 1zxl
(Freundlich et al., 2005) and 1uh5 (Swarna-
mukhi et al., 2004)], all of which display
strong structural similarity, in particular
around the NAD+-binding sites, to the
structure reported here. Moreover, in our
crystal form and all of the previously solved
PfENR structures, the loop region corre-
sponding to the low-complexity insert
common to the apicomplexan ENR family
between residues Ile240 and Thr283 cannot
be seen owing to disorder (Perozzo et al.,
2002; Pidugu et al., 2004). In contrast, the
smaller equivalent insert in TgENR
between helices 7 and 8 (Gly236–Lys241)
can be seen in subunit A, where it forms a
loop that caps the ends of both helices and
lies close to the bound inhibitor, but makes
no direct contacts. The loop is linked to the
flanking residues by a number of hydrogen
bonds and an ion-pair interaction between
the side chains of Lys241 and Asp249.
Inspection of the ENR sequences from the
majority of apicomplexan parasites shows
an apparent conservation of Lys237 and of
an SGE motif (Ser238–Glu240; Fig. 2).
However, the difference in insert size makes
it difficult to envisage conservation of the
position of the SGE motif within the
apicomplexan family and the sequence similarity may be only
a chance resemblance. Interestingly, examination of an elec-
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Figure 4
2Fobs  1Fcalc electron-density maps for (a) PfENR and (b) TgENR contoured at 0.8
produced after initial rigid-body refinement in REFMAC5 (Murshudov et al., 1997). Both
NAD+ and triclosan were omitted from the model during refinement, but are represented in
stick format in order to show their unambiguous position in the initial electron-density maps.
(c) Stereo diagram of the residues responsible for forming a hydrogen-bonding network to the
NAD+ cofactor in subunit A of TgENR. (d) Stereo diagram of the triclosan-binding site of
subunit A of TgENR, with the active-site residues Tyr179, Tyr189, Lys197 and Phe243 labelled.
(c) and (d) use the colour scheme yellow, red, blue, green and orange for carbon, oxygen,
nitrogen, chlorine and phosphorus, respectively, and were produced in TURBO-FRODO
(Roussel et al., 1990).
trostatic charge potential surface of a TgENRmonomer shows
that the face of the putative fatty-acid binding pocket is lined
with several positively charged residues, including Lys237.
Moreover, recent studies have strongly implicated helix 8
and its preceding residues (which would include the inserted
region in apicomlexan parasites) in forming interactions with
the acyl carrier protein, suggesting that Lys237 may play a role
in binding the predominantly negatively charged acyl carrier
protein (Rafi et al., 2006; Fig. 3b).
3.2. The nicotinamide adenine dinucleotide-binding and
triclosan-binding sites in PfENR and TgENR
Analysis of the electron-density maps in the region of the
active site showed good density for the entire nucleotide
cofactor and for the triclosan inhibitor in all subunits of the
P. falciparum and T. gondii ENR enzymes, allowing their
unambiguous positioning (Figs. 4a and 4b). The cofactor is
bound in an extended conformation, with both ribose sugar
rings adopting a C20-endo conformer and the nicotinamide
ring adopting a syn conformation. In TgENR, the adenine ring
binds within a pocket formed by the main-chain atoms of
residues Gly16–Ala18, Leu79–Ala82 and Leu128–Asn130 and
by the side chains of residues Asp80, Asn130 and Asn152, with
one face of the adenine ring forming – stacking interactions
with Trp43 and with Leu128 making van der Waals inter-
actions with the other face (Fig. 4c). The pyrophosphate
moiety makes interactions with the main chain of Gly22, Tyr23
and Ala231, the side-chain atoms of Asp19, Ser229 and
Ala231 and the dichloro ring of triclosan. The nicotinamide
ribose moiety forms packing interactions with Tyr23, Ser127,
Ala129, Leu177 and Lys197 and the bound inhibitor triclosan
and forms a hydrogen bond from the nicotinamide ribose to
the main-chain N atom of Leu128. The nicotinamide ring
forms interactions with the side-chain atoms of Tyr23, Tyr179,
Ala224 and Ser229 and with the main chain of Ser178, Ala224,
Gly225, Pro226 and Leu227, with additional – stacking
interactions with the 4-chlorophenoxy ring of triclosan. In
addition to an extensive hydrogen-bonding network within the
NAD+-binding site, Leu227 forms two hydrogen bonds from
its main-chain N and carbonyl O atoms to the amide O and N
atoms of the nicotinamide, allowing the orientation to be
unambiguously determined (Fig. 4c). The only significant
difference in the binding of the NAD+ cofactor between
T. gondii and P. falciparum ENR is the positioning of Arg235
within PfENR, which in subunit D forms additional hydrogen
bonds to the ribose moiety of the NAD+ that are not seen in
the other subunits.
The mode of triclosan binding to both PfENR and TgENR
is very similar, with the 4-chlorophenoxy ring of the triclosan
in TgENR forming van der Waals interactions with the side
chains of Tyr179, Tyr189, Pro226, Ala232, Ile235, Phe243 and
Ile244. The triclosan 2,4-dichlorophenoxy ring is located
within a pocket formed by the peptide backbone of residues
Leu128–Ala131, the pyrophosphate and nicotinamide
moieties of NAD+ and the side chains of Val134, Met193,
Lys197, Ala231 and Ile235 (Fig. 4d).
3.3. Analysis of the apo TgENR structure
The overall fold of the apo TgENR structure is similar to
that of the TgENR–NAD+–triclosan complex, with an r.m.s.d.
of the C atoms of 0.5 A˚, and as such will not be described in
detail. The most significant difference is the disorder of resi-
dues Lys228–Lys241, which form an ordered loop in the
TgENR–NAD+–triclosan complex, with Ala230–Ser232
forming a helix which packs against the triclosan inhibitor.
This ordering of the loop region upon inhibitor binding has
been seen within the bacterial and plant ENR family and has
been implicated in the slow tight binding behaviour of
triclosan (Seefeld et al., 2003; Levy et al., 2001; Qiu et al., 1999;
Roujeinikova et al., 1999). Furthermore, PfENR has also been
shown to display a two-step inhibition mechanism, with the
initial formation of a stable triclosan complex being followed
by a conformational change in the loop region, creating a tight
inhibitor complex (Kapoor et al., 2004). The only other
difference is a slight movement of residues Trp43–Ser69, with
Trp43 adopting a position such that it makes stacking inter-
actions with the adenine ring of the NAD+ cofactor in the
TgENR–NAD+–triclosan complex but is in a different posi-
tion in the TgENR apo form.
3.4. Comparison of the apicomplexan ENR structures to
those of other species
In order to investigate the similarities and differences
between members of the ENR family, the structures of the
B. napus, Escherichia coli, T. gondii and P. falciparum
enzymes in complex with NAD+ and triclosan were compared.
As might be expected on the basis of their sequence similarity,
the parasite ENRs are more closely related to the plant and
cyanobacterial enzymes than those of bacterial origin, with
both containing significant inserts both before and after 3
compared with their bacterial counterparts. The second of
these inserts, which includes 3, is involved in the formation of
a large groove around one of the twofold axes of the ENR
tetramer which is absent in the bacterial ENR enzymes (Fig. 5).
Furthermore, analysis of the ENR sequences from several
plant, Plasmodium, Eimeria and Toxoplasma species reveals
that the insert shows strong overall sequence conservation and
moreover that all the sequences contain an R/KxNKRY motif.
The position of this motif is such that the residues directly
follow 3 and are all solvent-exposed, with the insert being
unique to the ENR of plastid-containing organisms. A further
striking feature of the surface-potential calculations is the
overall positive charge of PfENR (pI 8.2) when compared with
the T. gondii, B. napus and E. coli enzymes, whose pI values
are 6.3, 5.4 and 5.6, respectively (Fig. 5). However, a role for
the structural conservation of a large groove around one of the
twofolds in the plant and apicomplexan ENRs has yet to be
determined.
3.5. Conservation of water in the active site
In a proposed mechanism of catalysis for the short-chain
dehydrogenase reductase (SDR) family, to which ENR
belongs, a key role is played by two water molecules within the
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active site which form part of a proton-relay system to the bulk
solvent which replenishes the proton donated to the substrate
by the catalytic tyrosine (Benach et al., 1998; Filling et al., 2002;
Price et al., 2004; Schlieben et al., 2005). Moreover, the
superposition of 3/17-hydroxysteroid dehydrogenase, a
member of the SDR family, onto PfENR reveals the strong
spatial conservation of a water molecule next to the conserved
catalytic Lys residue, with close spatial conservation of the
second water molecule (Fig. 6a). These two waters reside in a
pocket formed by nine residues (His131, Leu133, Ala134,
Ser158, Ser159, Ser181, Leu182, Lys202
and Leu205), all of which are fully
conserved within the T. gondii and
Plasmodium ENR family, with the
spatial conservation of both water
molecules in E. coli, Helicobacter
pylori, M. tuberculosis and B. napus
ENRs (PDB codes 1d8a, 1jvf, 1bvr and
1d70, respectively; Fig. 6a).
3.6. Inhibitor binding and
conformational flexibility in the
structure of ENR
The program ESCET (Schneider,
2000) was used to compare the position
of the C atoms in the EcENR–NAD+
complex and the various EcENR–
inhibitor complexes that have been
solved through co-crystallization, which
includes the diazaborines, triclosan and
the aminopyridine derivative compound
29 [(E)-N-methyl-N-(1-methyl-1H-indol-
3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-
1,8-naphthyridin-3-yl)acrylamide] (See-
feld et al., 2003; Levy et al., 1999;
Heerding et al., 2001). All other inhi-
bitor complexes [imidazole (Miller et al.,
2002) and benzamide-based inhibitors
(Payne et al., 2002)] were ignored owing
to the observation that for ENR inhi-
bitor soaking and co-crystallization are
not equivalent (Heerding et al., 2001).
This comparison showed only one
region of difference, around the inhi-
bitor-binding site between residues 190–
209 in EcENR (229–249 in TgENR),
corresponding to 6 and 7 (7 and 8
in the Tg and Pf enzymes) and the
flanking residues (Fig. 6b). In the
structure of the EcENR–NAD+
complex and in the TgENR apo
enzyme, this region corresponds to a
disordered loop. However, on binding
of inhibitors belonging to the diaza-
borine or aminopyridine family or
triclosan, residues 190–198 in EcENR
adopt a helical structure (Seefeld et al.,
2003; Levy et al., 2001; Qiu et al., 1999;
Roujeinikova et al., 1999). Furthermore,
comparing the structures of the various
inhibitor complexes reveals that in the
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Figure 5
A representation of the surface potential and structure of the E. coli, B. napus, T. gondii and
P. falciparum ENR tetramers. The large groove present in the parasite and plant ENR enzymes is
formed by an insert after helix 3, which is not found within the bacterial ENR family. All four
structures are on the same scale and are coloured by electrostatic charge, with red and blue
representing negative and positive charges, respectively.
E. coli enzyme both helices 6 and 7 and their connecting
polypeptide chain adopt significantly different positions which
appear to be associated with the size and position of the
inhibitor, with Gly199, Ile200, Lys201, Phe203 and Met206
showing the greatest movements. In addition, those residues
within the E. coli enzyme that show a significant change in the
side-chain conformation between the structures of the various
inhibitor complexes are a subset of those residues that display
the greatest main-chain flexibility.
Analysis of the inhibitor-binding pocket for both PfENR
and TgENR reveals that both are very similar, with only one
sequence difference at position 131 (TgENR numbering), a
residue that points away from the pocket, in which Ala is
replaced by Gly. Analysis of the sequence conservation across
the ENR family of the 11 residues shown to be involved in
binding compound 29 in EcENR (Gly93, Phe94, Ala95,
Leu101, Tyr146, Tyr156, Met159, Ala196, Ile200, Lys201 and
Met206) reveals that three residues are not conserved
(Met206, Lys201 and Leu101). In contrast, of the ten residues
which make up the triclosan-binding pocket in EcENR
(Gly93, Phe94, Ala95, Tyr146, Tyr156, Lys163, Ala196, Ala197,
Ile200 and Phe203), all are either fully or strongly conserved.
3.7. Implications of the apicomplexan ENR
structure for drug design
Modelling studies on TgENR using the
aminopyridine-based inhibitor compound
29 (Seefeld et al., 2003) suggests that if the
inhibitor were bound in the same position as
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Figure 6
(a) Stereoview of the complexes of ENR from
P. falciparum (red), B. napus (magenta) and E. coli
(green) with NAD+ and triclosan and of
M. tuberculosis ENR in complex with NAD+
(yellow) and with NAD+ and C-16 fatty-acid
substrate, labelled C-16 (blue). In addition to
ENR, the catalytic Lys and Tyr residues of the 3/
17-hydroxysteroid dehydrogenase SDR enzyme
are shown (orange). The positions of two apparently
conserved water molecules in the active site of each
of these enzymes are shown as coloured spheres.
The water molecules in ENR form interactions with
several active-site residues, including the catalytic
lysine and the 30-OH of the NAD+ nicotinamide
ribose. (b) Stereoview of the differences in position
for the substrate-binding helix (6 or 7 in the
bacterial and plant/parasite ENRs, respectively)
upon the binding of different inhibitors to EcENR.
The loop region which moves upon inhibitor
binding and the corresponding inhibitor in the
EcENR complex is coloured cream, green, red and
blue for benzo-diazaborine, triclosan, compound 29
and imidazole, respectively. For clarity, only those
residues which make direct interactions with the
inhibitors in one or more complexes are shown in
stick representation and numbered. (c) Close-up of
the E. coli ENR–NAD+–compound 29 complex
(red), E. coli ENR–NAD+–triclosan complex
(green) and T. gondii ENR–NAD+–triclosan
complex (yellow) superimposed, with critical resi-
dues involved in inhibitor binding shown in stick
representation with the TgENR structure
numbered. Modelling of compound 29 into the
structure of TgENR in complex with NAD+ (black)
and triclosan shows that a severe steric clash might
occur owing to the difference in the structure close
to Phe242, which in EcENR is replaced by Asp202.
(d) Representation of the van der Waals surfaces of
the protein (coloured red) within the active site of
E. coli, T. gondii and P. falciparum ENR close to the
phenolic ring of triclosan (blue). Both the
P. falciprum and T. gondii ENRs appear to be less
closely packed with triclosan owing to the presence
of an alanine residue at the base of the binding
pocket in contrast to the bulkier methionine residue
in the E. coli enzyme.
seen in EcENR there would be likely to be severe clashes with
residues Ala231, Ile235, Phe243, Ile244 and Ala247. However,
if the structure of TgENR is as flexible as that of EcENR, then
this steric hindrance may be relieved to some extent by the
movement of 7 and 8. However, even then an adverse
contact with the side chain of Phe243 which lies at the start of
8 in TgENR and makes van der Waals contact with the
chlorine of the 4-chlorophenoxy ring of triclosan might remain
(Fig. 6c). In EcENR and other members of the bacterial ENR
family, the residue at this position is smaller (Gly, Asn or Asp)
and points towards the solvent.
Sequence analysis of the ENR family shows that in the
region of the inhibitor-binding pocket the bacterial and plant
ENR sequences all contain a bulky hydrophobic residue (Met,
Leu or Ile) close to the 4-chlorophenoxy ring of triclosan,
whereas the ENRs of apicomplexan species such as T. gondii
and Plasmodium have a fully conserved alanine residue (Fig. 2
and Fig. 6d). This sequence change produces an increase in the
space at the base of the binding pocket and reduces the van
der Waals packing interactions with the triclosan and amino-
pyridine-based inhibitors in comparison to other members of
the ENR family (Fig. 6d). Analysis of the structure suggests
that the production of a triclosan analogue containing more
bulky constituents to replace the Cl atom at the 4-position of
the chlorophenoxy ring might allow the van der Waals
contacts to be enhanced, improving inhibitor binding. Indeed,
recent studies have shown that whilst subtle changes at this
position did not improve inhibitor binding, the effects were
markedly different between PfENR and ENRs of bacterial
origin (Chhibber et al., 2006; Sullivan et al., 2006; Freundlich et
al., 2005, 2006). This finding may allow the development of
novel ENR inhibitors that have a significantly higher affinity
for the apicomplexan ENR family, which have been shown in
this study to have a significantly similar binding-site archi-
tecture.
4. Conclusion
The structures of both PfENR and TgENR have permitted a
detailed comparison to be made between members of the
apicomplexan, plant and bacterial ENR families. This has
revealed that the apicomplexan enzymes differ in the active-
site region when compared with those of bacterial origin. This
would suggest that ENR inhibitors developed as part of an
antibacterial program might require optimization in order to
act as antiparasitic agents. Despite these apparent problems,
the prospect for the design of a family of drugs which could
target the apicomplexan parasites is good and the current
study has provided a toolkit which could be utilized by future
drug-discovery programs.
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